UCB recently announced that the U.S. Food and Drug Administration (FDA) has approved BIMZELX ® (bimekizumab-bkzx) for the treatment of moderate-to-severe hidradenitis suppurativa (HS) in adults. This approval is significant
A recent study published in the Journal of Drugs in Dermatology has highlighted a six-step skincare regimen that improves signs of photoaging. This skincare regimen, called Essential Six (RATIONALE), includes
A recent study published in JAMA Dermatology has evaluated the relationship between precocious puberty and hidradenitis suppurativa (HS) in pediatric patients. Drawing on data from the Explorys databases, the study
The U.S. Food and Drug Administration (FDA) has granted BPGbio a Rare Pediatric Disease Designation for BPM31510T, its investigational treatment for epidermolysis bullosa (EB). This news brings hope to the EB
A recent study published in the Journal of the American Medical Association (JAMA Dermatology) found that patients with newly diagnosed alopecia areata (AA) have a higher prevalence and incidence of
Allergan Aesthetics has announced that the U.S. Food and Drug Administration (FDA) has approved BOTOX® Cosmetic for temporary improvement in the appearance of moderate-to-severe vertical bands connecting the jaw and neck
A study conducted in patients with chronic hand eczema (CHE) revealed that topical corticosteroid (TCS) phobia is a great concern, with many fearing future health risks associated with this type
A new phase 2b study is currently underway to evaluate rezpegaldesleukin (REZPEG), an interleukin-2 receptor pathway agonist, for the treatment of severe to very severe alopecia areata (AA). This comes after REZPEG showed
In a study recently presented at the European Academy of Dermatology and Venerology (EADV) Congress 2024, it was revealed that semaglutide has the potential to treat hidradenitis suppurative (HS) in
In a press release from Arcutis Biotherapeutics, Inc., they have announced that the U.S. Food and Drug Administration (FDA) has accepted its sNDA for ZORYVE (roflumilast) foam 0.3% for the
Eli Lilly has announced that EBGLYSS ™ (lebrikizumab-lbkz) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate-to-severe atopic dermatitis in adults and children
A team of expert dermatologists recently drafted recommendations for managing atopic dermatitis (AD) to optimize treatment outcomes. They noted that current treat-to-target recommendations for AD “may not include high enough
The National Psoriasis Foundation has released a Psoriasis Health Indicator Report detailing the health impacts of psoriasis. The report includes information and data on psoriasis, its health outcomes, prevention of
The U.S. Food and Drug Administration (FDA) has warned consumers against the purchase and use of certain chemical peel skin products without first consulting a professional due to the risk
The U.S. Food and Drug Administration (FDA) has approved Galderma’s Nemluvio® (nemolizumab) as a pre-filled pen for subcutaneous injection for the treatment of prurigo nodularis in adults. The FDA had previously
In a recent article published in the Dermatology Times, Zoe Diana Draelos, MD, addressed some of the complex issues surrounding the physiologic differences in skin across various ethnic groups. Dr.
According to a recent study, increasing the intake of omega-3 fatty acids through dietary intervention and supplementation may alleviate acne severity. Over a 16-week period, researchers conducted a study which
Sun Pharmaceutical Industries Limited recently announced that the U.S. Food and Drug Administration (FDA) has approved LEQSELVI™ (deuruxolitinib) 8 mg tablets for the treatment of severe alopecia areata in adults. LEQSELVI
In a recent study published in the Journal of Investigative Dermatology, researchers employed X-ray crystallography to gain insights into how bimekizumab (Bimzelx; UCB) binds to interleukin (IL)-17F. Adams et al
Arcutis Biotherapeutics, Inc. recently announced that the U.S. Food and Drug Administration (FDA) has approved ZORYVE® (roflumilast) Cream 0.15% for the treatment of mild-to-moderate atopic dermatitis (AD) in adult and
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.
LiVDerm / South Beach Symposium
1801 N Military Trail, Ste 110
Boca Raton, FL, 33431
Copyright © 2025, LiVDerm. All Rights Reserved.
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.
